Certolizumab Pegol is a pegylated anti-TNF drug without an Fc fragment. PEGylation involves the addition of polyethylene glycol as a ‘transporter’, which gives advantages from the pharmacokinetic point of view.10,11 This could explain its effectiveness when other anti-TNF drugs have failed. Uveitis is a condition that can have serious consequences. Therefore, the capacity to use a new drug for ...

conclusions cp is effective for inducing clinical response and maintenance of clinical remission in patients with moderate to severe cd with similar side-effect profile as the control arms. background tumor necrosis factor-α (tnf-α) antibodies are currently used in patients with moderate to severe crohn’s disease (cd) who are unresponsive to conventional therapies. certolizumab pegol (cp) is on...

We present EULAR sessions on the latest treatments for rheumatic disease with an infliximab biosimilar, certolizumab pegol, secukinumab, and bimekizumab. We also report on significant developments in diabetes presented at ADA's Scientific Sessions.

Treatment outcomes in rheumatoid arthritis (RA) have improved considerably with the use of biological therapies. Since the discovery of the role of tumor necrosis factor (TNF) alpha in the pathogenesis of the disease, three TNF inhibitors, infliximab, etanercept and adalimumab, have become widely used for the treatment of RA. More recently, two newer TNF inhibitors-certolizumab pegol and golimu...

Anti-tumor necrosis factor α (TNF-α) biologic agents are used for treating refractory sarcoidosis. However, sarcoidosis-like epithelioid cell granulomas may develop during anti-TNF-α treatment. A 63-year-old man suffering from rheumatoid arthritis was treated with oral methotrexate and methylprednisolone for 4 years. He subsequently started biweekly subcutaneous injections of certolizumab pegol...

Monoclonal antibodies against TNFα, including infliximab, adalimumab, golimumab, and certolizumab pegol, are widely used for the treatment of the inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Recently, the crystal structures of TNFα, in complex with the Fab fragments of infliximab and adalimumab, have revealed the molecular mechanisms of these antibody drugs...

Adalimumab is the only FDA- and EMA-approved treatment for moderate to severe hidradenitis suppurativa (HS), where etanercept certolizumab-pegol have been shown be inefficacious, suggesting that mechanism of action (MOA) adalimumab distinct in HS may contribute improved wound healing. We demonstrated adalimumab, but neither nor certolizumab-pegol, induces a healing profile vitro by regulating m...

We present the case of a 56-year-old black woman with rheumatoid arthritis who developed worsening fatigue, fever, weight loss, and a vesiculobullous skin eruption while being treated with certolizumab pegol for her arthritis. Microscopic findings confirmed the diagnosis of a neutrophilic dermatosis.

BACKGROUND Anti-tumour necrosis factor-alpha agents (anti-TNF) are effective therapies for the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. AIM To perform a network meta-analysis comparing the efficacy of anti-TNF therapies in CD. METHODS After screening 506 studies, reviewers extracted information on 10 studies. Traditional meta-analysis (TMA) was used to c...